NCT01081912

Brief Summary

The purpose of the study is to evaluate the safety and efficacy of Hydrocodone Bitartrate controlled-release capsules in subjects with chronic low back pain.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
510

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Mar 2010

Geographic Reach
1 country

51 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2010

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

March 4, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 5, 2010

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2011

Completed
2.6 years until next milestone

Results Posted

Study results publicly available

April 21, 2014

Completed
Last Updated

December 8, 2022

Status Verified

March 1, 2014

Enrollment Period

1.6 years

First QC Date

March 4, 2010

Results QC Date

February 4, 2014

Last Update Submit

November 8, 2022

Conditions

Keywords

chronic painback pain

Outcome Measures

Primary Outcomes (1)

  • Mean Change in 24-hour Pain Intensity Ratings Scale (NRS).

    Change in average pain intensity as measured daily by Numeric Rating Scale (NRS) for Pain (0-10; where 0 = no pain, 10 = worst pain imaginable) comparing HC-ER with Placebo. Lower number equals better outcome.

    Baseline to Day 85 (Treatment Phase)

Secondary Outcomes (1)

  • Mean Change of the Clinic NRS Pain Intensity

    Baseline to Day 85 visit

Study Arms (2)

Hydrocodone Bitartrate Capsules

ACTIVE COMPARATOR

Hydrocodone Bitartrate Controlled-Release Capsules

Drug: Hydrocodone bitartrate

Placebo comparator

PLACEBO COMPARATOR
Drug: Placebo

Interventions

Capsules, no active substance, shells identical to active comparator capsules

Also known as: Sugar pill
Placebo comparator

dosage form: capsule Strengths 10mg, 20mg, 30mg, 40mg, 50mg

Hydrocodone Bitartrate Capsules

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects must have a clinical diagnosis of moderate to severe chronic lower back pain (CLBP)
  • Subjects must be classified as non-neuropathic, neuropathic, or symptomatic for more than 6 months after lower back pain (LBP) surgery
  • Subjects must in the Investigator's opinion qualify for around-the-clock opioid therapy for treatment of their chronic lower back pain (CLBP).
  • Subjects must have been taking opioids for at least 5 days/week for the past 4weeks
  • Subjects must have an average Clinic Pain Score of ≥ 4 on the 11-point (0-10) numeric rating scale (NRS) as an average for the last 24 hours of Screening
  • Subjects, in the opinion of the Investigator, must be considered to be in generally good health other then CLBP at Screening
  • Female subjects of childbearing potential must have a negative urine pregnancy test at the Screening Visit, and must consent to use a medically-acceptable method of contraception throughout the entire study period.
  • Subjects must voluntarily provide written informed consent.

You may not qualify if:

  • Any clinically significant condition that would, in the opinion of the Investigator, preclude study participation or interfere with the assessment of pain and other symptoms of CLBP or increase the risk of opioid-related adverse events
  • A medical condition that, in the opinion of the Investigator, would compromise the subject's ability to swallow, absorb, metabolize, or excrete the study drug
  • A surgical procedure for back pain within 6 months
  • A nerve or plexus block, including epidural steroid injections or facet blocks
  • A history of chemotherapy or confirmed malignancy within past 2 years
  • Any other chronic pain condition other than CLBP that, in the Investigator's opinion, would interfere with the assessment of LBP e.g. fibromyalgia, osteoarthritis, rheumatoid arthritis, migraine headaches requiring opioid treatment
  • Uncontrolled blood pressure, i.e., subject has a sitting systolic blood pressure \>180 mmHg or \<90 mmHg, and/or a sitting diastolic blood pressure \>120 mmHg or \<50 mmHg at Screening
  • A Body Mass Index (BMI) \>45 kg/m2
  • A Hospital Anxiety and Depression Scale (HADS) Index score of \>12 in either depression or anxiety subscales or an established history of major depressive disorder that is poorly controlled with medication
  • A clinically significant abnormality in clinical chemistry, hematology or urinalysis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (51)

Arizona Research Center

Phoenix, Arizona, 85023, United States

Location

Clopton Clinic

Jonesboro, Arkansas, 72401, United States

Location

Advanced Clinical Research Institute

Anaheim, California, 92801, United States

Location

Neuro-Pain Medical Center, Inc.

Fresno, California, 93710, United States

Location

Pacific Coast Pain Management Center

Laguna Hills, California, 92637, United States

Location

Clinicos, LLC

Colorado Springs, Colorado, 80904, United States

Location

Interwest Rehabilitation, LLC

Littleton, Colorado, 80122, United States

Location

Stamford Therapeutics Consortium

Stamford, Connecticut, 06905, United States

Location

Clinical Research of West Florida, Inc.

Clearwater, Florida, 33765, United States

Location

Florida Institute of Medical Research

Jacksonville, Florida, 32257, United States

Location

Peninsula Research, Inc.

Ormond Beach, Florida, 32174, United States

Location

Gold Coast Research

Plantation, Florida, 33317, United States

Location

Clinical Research of West Florida, Inc.

Tampa, Florida, 33603, United States

Location

Perimeter Institute for Clinical Research, Inc.

Atlanta, Georgia, 30338, United States

Location

River Birch Research Alliance, LLC

Blue Ridge, Georgia, 30513, United States

Location

Georgia Institute for Clinical Research, LLC

Marietta, Georgia, 30060, United States

Location

Georgia Clinical Research

Snellville, Georgia, 30078, United States

Location

Suburban Clinical Research

Chicago, Illinois, 60490, United States

Location

Destiny Clinical Research, LLC

Evansville, Indiana, 47714, United States

Location

Integrated Clinical Trials Services, Inc.

West Des Moines, Iowa, 50265, United States

Location

International Clinical Research Institute

Leawood, Kansas, 66211, United States

Location

Clinical Trials Technology, Inc

Prairie Village, Kansas, 66206, United States

Location

Cotton O'Neil Clinical Research Center

Topeka, Kansas, 66606, United States

Location

Clinical Trials Management

Metairie, Louisiana, 70006, United States

Location

Best Clinical Trials, LLC

New Orleans, Louisiana, 70115, United States

Location

River Cities Clinical Research Center

Shreveport, Louisiana, 71105, United States

Location

NECCR Internal Medicine & Cardiology Associates, LLC

Fall River, Massachusetts, 02720, United States

Location

Center for Clinical Trials

Biloxi, Mississippi, 39531, United States

Location

Research West, LLC

Kalispell, Montana, 59901, United States

Location

Office of Danka Michaels, MD

Las Vegas, Nevada, 89128, United States

Location

South Jersey Medical Associates

Blackwood, New Jersey, 08012, United States

Location

CRI Worldwide, LLC

Willingboro, New Jersey, 08046, United States

Location

Five Towns Neuroscience Research

Cedarhurst, New York, 11516, United States

Location

Upstate Clinical Research Associates

Williamsville, New York, 14221, United States

Location

Center for Clinical Research LLC

Winston-Salem, North Carolina, 27103, United States

Location

IVA Research

Cincinnati, Ohio, 45245, United States

Location

Prestige Clinical Research

Franklin, Ohio, 45005, United States

Location

Neuropsychiatric Research Center

Oklahoma City, Oklahoma, 73109, United States

Location

Brandywine Clinical Research

Downingtown, Pennsylvania, 19335, United States

Location

Feasterville Family Health Care Center

Feasterville, Pennsylvania, 19053, United States

Location

New England Center for Clinical Research

Cranston, Rhode Island, 02920, United States

Location

Health Concepts

Rapid City, South Dakota, 57702, United States

Location

Integrity Clinical Research, LLC

Milan, Tennessee, 38358, United States

Location

InSite Clinical Research

DeSoto, Texas, 75115, United States

Location

Clinical Trial Network

Houston, Texas, 77074, United States

Location

Innovative Clinical Trials

San Antonio, Texas, 78229, United States

Location

Invisions Consultants, LLC

San Antonio, Texas, 78229, United States

Location

Clinical Trial Network

Spring, Texas, 77386, United States

Location

Advanced Research Institute

Ogden, Utah, 84405, United States

Location

Hypothe Test, LLC

Roanoke, Virginia, 24018, United States

Location

Northwest Clinical Research Center

Bellevue, Washington, 98007, United States

Location

MeSH Terms

Conditions

Chronic PainBack Pain

Interventions

SugarsHydrocodone

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

CarbohydratesCodeineMorphine DerivativesMorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic Compounds

Results Point of Contact

Title
Kevin Romanko
Organization
Zogenix

Study Officials

  • Kevin Romanko, DPM

    Zogenix, Inc.

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
GT60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 4, 2010

First Posted

March 5, 2010

Study Start

March 1, 2010

Primary Completion

October 1, 2011

Study Completion

October 1, 2011

Last Updated

December 8, 2022

Results First Posted

April 21, 2014

Record last verified: 2014-03

Locations